Research graph
References from BCX9250 is a potent small-molecule inhibitor of Activin A Receptor Type 1 (ACVR1/ALK2) for fibrodysplasia ossificans progressiva. Local targets link to admitted publications; unresolved targets remain external evidence.
Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity
10.7554/elife.40814 · 2018 · External reference
Fibrodysplasia ossificans progressiva: clinical and genetic aspects
10.1186/1750-1172-6-80 · 2011 · External reference
Fibrodysplasia ossificans progressiva (FOP): watch the great toes!
10.1007/s00431-010-1232-5 · 2010 · External reference
Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1(R206H) fibrodysplasia ossificans progressiva (FOP) mutation
10.1002/jbmr.2820 · 2016 · External reference
The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment
10.1002/jbmr.2728 · 2016 · External reference
ACVR1 function in health and disease
10.3390/cells8111366 · 2019 · External reference
Accumulated knowledge of activin receptor-like kinase 2 (ALK2)/activin A receptor, type 1 (ACVR1) as a target for human disorders
10.3390/biomedicines9070736 · 2021 · External reference
Cellular hypoxia promotes heterotopic ossification by amplifying BMP signaling
10.1002/jbmr.2848 · 2016 · External reference
Immunologic aspects in fibrodysplasia ossificans progressiva
10.3390/biom14030357 · 2024 · External reference
Intersections of fibrodysplasia ossificans progressiva and traumatic heterotopic ossification
10.3390/biom14030349 · 2024 · External reference
When limb surgery has become the only life-saving therapy in FOP: a case report and systematic review of the literature
10.3389/fendo.2020.00570 · 2020 · External reference
From mysteries to medicines: drug development for fibrodysplasia ossificans progressive
10.1517/21678707.2013.825208 · 2013 · External reference
Druggable targets, clinical trial design and proposed pharmacological management in fibrodysplasia ossificans progressiva
10.1080/21678707.2020.1751122 · 2020 · External reference
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial
10.1038/s41591-023-02561-8 · 2023 · External reference
Fibrodysplasia ossificans progressiva: a challenging diagnosis
10.3390/genes12081187 · 2021 · External reference
A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva
10.1038/ng1783 · 2006 · External reference
Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1
10.1002/humu.20868 · 2009 · External reference
BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP)
10.1002/dvdy.387 · 2022 · External reference
TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease
10.1038/boneres.2016.9 · 2016 · External reference
Specification of BMP signaling
10.3390/cells8121579 · 2019 · External reference
The obligatory role of activin A in the formation of heterotopic bone in fibrodysplasia ossificans progressiva
10.1016/j.bone.2017.06.011 · 2018 · External reference
The expansion of heterotopic bone in fibrodysplasia ossificans progressiva is activin A-dependent
10.1002/jbmr.3235 · 2017 · External reference
ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A
10.1126/scitranslmed.aac4358 · 2015 · External reference
The role of activin A in fibrodysplasia ossificans progressiva: a prominent mediator
10.1042/bsr20190377 · 2019 · External reference
Garetosmab, an inhibitor of activin-A, reduces formation of heterotopic bone and soft tissue flare-ups in patients with fibrodysplasia ossificans progressiva
2020 · External reference
Garetosmab reduces flare-ups in patients with fibrodysplasia ossificans progressiva
10.1210/jendso/bvab048.512 · 2021 · External reference
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
10.1172/jci.insight.95042 · 2021 · External reference
BMP type I receptor inhibition reduces heterotopic [corrected] ossification
10.1038/nm.1888 · 2008 · External reference
Inhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification
10.1073/pnas.1515397113 · 2016 · External reference
An mTOR signaling modulator suppressed heterotopic ossification of fibrodysplasia ossificans progressiva
10.1016/j.stemcr.2018.10.007 · 2018 · External reference
Development of an ALK2-biased BMP type I receptor kinase inhibitor
10.1021/cb300655w · 2013 · External reference
Reduction of new heterotopic ossification (HO) in the open-label, phase 3 MOVE trial of palovarotene for fibrodysplasia ossificans progressiva (FOP)
10.1002/jbmr.4762 · 2023 · External reference
Retinoid agonists in the targeting of heterotopic ossification
10.3390/cells10113245 · 2021 · External reference
Generation of a mouse with conditionally activated signaling through the BMP receptor, ALK2
10.1002/dvg.20201 · 2006 · External reference
MyD88 is not required for muscle injury-induced endochondral heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva
10.3390/biomedicines9060630 · 2021 · External reference
Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice
10.1182/blood-2011-03-339952 · 2011 · External reference
Iron metabolism and iron disorders revisited in the hepcidin era
10.3324/haematol.2019.232124 · 2020 · External reference
Animal models of fibrodysplasia ossificans progressiva
10.1002/dvdy.24606 · 2018 · External reference
Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons
2013 · External reference
Flare-up after maxillofacial surgery in a patient with fibrodysplasia ossificans progressiva: an [18F]-NaF PET/CT study and a systematic review
10.1002/jbm4.10008 · 2017 · External reference
Acute and chronic rapamycin use in patients with fibrodysplasia ossificans progressiva: a report of two cases
10.1016/j.bone.2017.12.011 · 2018 · External reference
An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva
10.1126/scitranslmed.abp8334 · 2024 · External reference
Animal models of fibrodysplasia ossificans progressiva
10.1002/dvdy.24606 · ExternalCitation · doi-reference
BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP)
10.1002/dvdy.387 · ExternalCitation · doi-reference
Generation of a mouse with conditionally activated signaling through the BMP receptor, ALK2
10.1002/dvg.20201 · ExternalCitation · doi-reference
Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1
10.1002/humu.20868 · ExternalCitation · doi-reference
Flare-up after maxillofacial surgery in a patient with fibrodysplasia ossificans progressiva: an [18F]-NaF PET/CT study and a systematic review
10.1002/jbm4.10008 · ExternalCitation · doi-reference
The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment
10.1002/jbmr.2728 · ExternalCitation · doi-reference
Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1(R206H) fibrodysplasia ossificans progressiva (FOP) mutation
10.1002/jbmr.2820 · ExternalCitation · doi-reference
Cellular hypoxia promotes heterotopic ossification by amplifying BMP signaling
10.1002/jbmr.2848 · ExternalCitation · doi-reference
The expansion of heterotopic bone in fibrodysplasia ossificans progressiva is activin A-dependent
10.1002/jbmr.3235 · ExternalCitation · doi-reference
Reduction of new heterotopic ossification (HO) in the open-label, phase 3 MOVE trial of palovarotene for fibrodysplasia ossificans progressiva (FOP)
10.1002/jbmr.4762 · ExternalCitation · doi-reference
Fibrodysplasia ossificans progressiva (FOP): watch the great toes!
10.1007/s00431-010-1232-5 · ExternalCitation · doi-reference
The obligatory role of activin A in the formation of heterotopic bone in fibrodysplasia ossificans progressiva
10.1016/j.bone.2017.06.011 · ExternalCitation · doi-reference
Acute and chronic rapamycin use in patients with fibrodysplasia ossificans progressiva: a report of two cases
10.1016/j.bone.2017.12.011 · ExternalCitation · doi-reference
An mTOR signaling modulator suppressed heterotopic ossification of fibrodysplasia ossificans progressiva
10.1016/j.stemcr.2018.10.007 · ExternalCitation · doi-reference
Development of an ALK2-biased BMP type I receptor kinase inhibitor
10.1021/cb300655w · ExternalCitation · doi-reference
TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease
10.1038/boneres.2016.9 · ExternalCitation · doi-reference
A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva
10.1038/ng1783 · ExternalCitation · doi-reference
BMP type I receptor inhibition reduces heterotopic [corrected] ossification
10.1038/nm.1888 · ExternalCitation · doi-reference
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial
10.1038/s41591-023-02561-8 · ExternalCitation · doi-reference
The role of activin A in fibrodysplasia ossificans progressiva: a prominent mediator
10.1042/bsr20190377 · ExternalCitation · doi-reference
Inhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification
10.1073/pnas.1515397113 · ExternalCitation · doi-reference
Druggable targets, clinical trial design and proposed pharmacological management in fibrodysplasia ossificans progressiva
10.1080/21678707.2020.1751122 · ExternalCitation · doi-reference
ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A
10.1126/scitranslmed.aac4358 · ExternalCitation · doi-reference
An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva
10.1126/scitranslmed.abp8334 · ExternalCitation · doi-reference
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
10.1172/jci.insight.95042 · ExternalCitation · doi-reference
Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice
10.1182/blood-2011-03-339952 · ExternalCitation · doi-reference
Fibrodysplasia ossificans progressiva: clinical and genetic aspects
10.1186/1750-1172-6-80 · ExternalCitation · doi-reference
Garetosmab reduces flare-ups in patients with fibrodysplasia ossificans progressiva
10.1210/jendso/bvab048.512 · ExternalCitation · doi-reference
From mysteries to medicines: drug development for fibrodysplasia ossificans progressive
10.1517/21678707.2013.825208 · ExternalCitation · doi-reference
Iron metabolism and iron disorders revisited in the hepcidin era
10.3324/haematol.2019.232124 · ExternalCitation · doi-reference
When limb surgery has become the only life-saving therapy in FOP: a case report and systematic review of the literature
10.3389/fendo.2020.00570 · ExternalCitation · doi-reference
Intersections of fibrodysplasia ossificans progressiva and traumatic heterotopic ossification
10.3390/biom14030349 · ExternalCitation · doi-reference
Immunologic aspects in fibrodysplasia ossificans progressiva
10.3390/biom14030357 · ExternalCitation · doi-reference
MyD88 is not required for muscle injury-induced endochondral heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva
10.3390/biomedicines9060630 · ExternalCitation · doi-reference
Accumulated knowledge of activin receptor-like kinase 2 (ALK2)/activin A receptor, type 1 (ACVR1) as a target for human disorders
10.3390/biomedicines9070736 · ExternalCitation · doi-reference
Retinoid agonists in the targeting of heterotopic ossification
10.3390/cells10113245 · ExternalCitation · doi-reference
ACVR1 function in health and disease
10.3390/cells8111366 · ExternalCitation · doi-reference
Specification of BMP signaling
10.3390/cells8121579 · ExternalCitation · doi-reference
Fibrodysplasia ossificans progressiva: a challenging diagnosis
10.3390/genes12081187 · ExternalCitation · doi-reference
Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity
10.7554/elife.40814 · ExternalCitation · doi-reference
